Is BPC-157 Legal in Michigan? How to Access It Through Legal Channels

What BPC-157 Is and Why People Seek It

BPC-157, short for Body Protection Compound-157, is a synthetic 15-amino-acid peptide derived from a protein found in human gastric juice. It does not exist as a natural supplement. Researchers have studied it primarily in animal models for wound healing, gut integrity, and tendon repair.

The Preclinical Evidence Base

Animal studies have produced attention-grabbing results. A 2018 paper in the Journal of Physiology and Pharmacology documented accelerated tendon-to-bone healing in rats given BPC-157 systemically, and a series of rodent studies has shown modulation of nitric oxide pathways relevant to tissue repair. [1] These findings are real, but they come from preclinical models. No peer-reviewed, randomized, placebo-controlled trial in humans has been published to demonstrate equivalent efficacy or long-term safety as of early 2025.

The absence of human trial data matters legally and clinically. The FDA's approval process requires that a drug demonstrate safety and efficacy in humans through controlled investigation. BPC-157 has not cleared that bar. [2]

Why the Interest Persists

Online communities focused on biohacking, sports performance, and peptide therapy have amplified anecdotal reports of faster injury recovery, reduced gut inflammation, and improved joint function. This social spread has driven demand well ahead of the science, creating a market that regulatory bodies are actively trying to address.

The Federal Legal Framework Governing BPC-157

BPC-157's legal status is controlled at the federal level. Michigan does not have a parallel drug-scheduling law that specifically addresses synthetic peptides, so understanding federal rules is the essential starting point.

FDA's Bulk Substances List and Category 2

The FDA regulates compounding pharmacies under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act). Compounding pharmacies may prepare customized drug preparations for patients using ingredients from an approved "bulk substances" list. [3]

In March 2023, the FDA finalized its placement of BPC-157 on the Category 2 bulk drug substances list for 503A compounding. Category 2 designation means the FDA has evaluated the substance and determined that available data do not support its use in compounding. [4] The specific concerns cited include the lack of adequate clinical evidence of safety and efficacy in humans and uncertainty about whether the substance presents risks that outweigh potential benefits.

A parallel restriction applies to 503B outsourcing facilities. BPC-157 is not on the 503B bulk substances list, which means licensed outsourcing facilities also cannot legally compound it for distribution. [5]

The practical result: as of early 2025, no licensed compounding pharmacy in the United States, including any operating in or shipping to Michigan, can legally prepare BPC-157 for human use under FDA guidelines.

Is BPC-157 a Scheduled Controlled Substance?

No. BPC-157 is not listed under the Controlled Substances Act schedules I through V. [6] It is not a narcotic, a stimulant, or a depressant under DEA scheduling. This distinction matters because it shapes enforcement posture. The primary federal authority over BPC-157 is the FDA, not the DEA.

The absence of DEA scheduling does not mean it is freely legal. A substance does not need to be a controlled substance to be regulated. The FD&C Act governs drugs, and any substance intended for use in humans to treat, cure, or prevent a condition is a drug under that definition. [2]

Research Chemical Status

Some vendors label BPC-157 as a "research chemical" to sidestep FDA oversight. This framing is legally thin. The FDA has stated clearly that labeling a substance "for research use only" or "not for human consumption" does not exempt it from the FD&C Act if the substance is intended, directly or indirectly, for human use. [2] Vendors who sell BPC-157 to consumers while being aware that consumers will inject it may be operating in violation of federal law.

Michigan-Specific Legal Considerations

Michigan does not have a state-level statute that specifically lists BPC-157 as a banned or controlled substance. The Michigan Department of Licensing and Regulatory Affairs (LARA) and the Michigan Board of Pharmacy operate within the federal framework. [7]

Michigan Board of Pharmacy and Compounding

Michigan compounding pharmacies are licensed by the Michigan Board of Pharmacy and must comply with both state pharmacy practice acts and federal law, including FDA guidance on bulk substances. Because BPC-157 is on the FDA's Category 2 list, a Michigan compounding pharmacy that prepared it for a patient would be operating in violation of federal compounding law regardless of any absence of a specific Michigan statute.

The Michigan Public Health Code, Act 368 of 1978, governs the practice of pharmacy in the state and incorporates compliance with federal standards as a condition of licensure. [7] A pharmacist who compounds a Category 2 substance risks disciplinary action, including license suspension.

Michigan Medical Practice Act and Physician Liability

Michigan physicians practice under the Michigan Public Health Code and are subject to discipline by the Michigan Board of Medicine. While a physician is not directly prohibited from discussing or researching BPC-157, prescribing or directing the use of a substance that cannot be legally dispensed creates significant professional and legal risk.

A physician who writes a direction for BPC-157 to be filled by an out-of-state vendor or gray-market source could face board discipline for facilitating the procurement of an unapproved drug outside lawful channels. The standard is whether the physician acted within accepted medical practice, and directing patients to unregulated online peptide suppliers does not meet that standard.

The HealthRX clinical team uses a three-tier access framework when evaluating any peptide therapy request from a Michigan patient. Tier 1 covers substances with FDA-approved forms or clear 503A eligibility, which can be prescribed and compounded through normal channels. Tier 2 covers substances on the FDA's Category 1 bulk list, which are under active review and may still be compounded with appropriate documentation. Tier 3 covers Category 2 substances like BPC-157, for which the current standard of care is to redirect patients toward evidence-based alternatives or, where appropriate, to enroll them in IRB-approved research.

Legal Access Paths That Do Exist

The restricted status of BPC-157 does not mean all access paths are closed. Two legitimate routes exist, though both have significant requirements.

IRB-Approved Clinical Research

Researchers affiliated with universities or academic medical centers in Michigan can study BPC-157 under an Institutional Review Board (IRB)-approved protocol. Participants in such studies receive the compound legally as part of the research, with full informed consent, safety monitoring, and protocol oversight.

As of January 2025, ClinicalTrials.gov lists a small number of studies involving BPC-157 globally, though none are large-scale Phase III trials. [8] Patients interested in research participation should search ClinicalTrials.gov for actively recruiting studies and consult with their physician about eligibility.

FDA Expanded Access (Compassionate Use)

The FDA's expanded access program allows individual patients to receive investigational drugs outside of clinical trials under specific circumstances, including serious conditions with no comparable alternative therapy. [9] This route requires a physician to submit an Investigational New Drug (IND) application for the individual patient, FDA approval of that application, and access to a manufacturer willing to supply the compound.

Given that BPC-157 has no current IND holder in the United States for the conditions typically sought by patients (tendon repair, gut healing), this path is theoretically available but practically very difficult to activate. The FDA approved 99% of expanded access requests in fiscal year 2023, but the bottleneck is finding a manufacturer with a valid IND. [9]

Risks of Gray-Market BPC-157 in Michigan

Patients who purchase BPC-157 from online vendors face several specific and documented risks.

Product Quality and Contamination

The FDA does not inspect or certify gray-market peptide vendors. A 2018 FDA analysis of peptide products sold online found that a significant proportion failed purity testing, contained wrong dosages, or were contaminated with bacterial endotoxins. [10] Bacterial endotoxins in injectable preparations can cause fever, sepsis, and life-threatening inflammatory responses.

BPC-157 is most commonly used by self-experimenters via subcutaneous injection, which creates a direct portal of entry for any contaminant present in the preparation.

Legal Risk to the Patient

Personal possession of an unapproved drug in the United States is generally not criminally prosecuted at the federal level for small quantities, but it is not risk-free. The FDA can seize shipments at the border, and vendors can face enforcement action that leaves patients without a supply they may have been relying on. Purchasing from foreign vendors also implicates import regulations under 21 CFR Part 312. [11]

No Physician Oversight

Self-administration without physician involvement removes the safety net of dosing guidance, contraindication screening, and adverse event recognition. Animal studies have used doses ranging from 2 micrograms per kilogram to 10 micrograms per kilogram body weight, but these numbers do not translate directly to human dosing, and no established human therapeutic dose exists.

Evidence Summary: What the Science Actually Shows

Understanding the evidence base helps contextualize why the FDA has not approved BPC-157 and why access restrictions exist.

Preclinical Findings

Rodent and rabbit studies have shown BPC-157 may accelerate healing in tendon, ligament, muscle, cornea, and intestinal tissue. A frequently cited 2016 study in the journal Molecules demonstrated significant reduction in colitis severity in rats, with effects attributed to modulation of the nitric oxide system. [1] A 2019 preclinical study showed protective effects on dopaminergic pathways in rodent models of Parkinson's-like neurodegeneration.

These findings are biologically plausible and scientifically interesting. They are not sufficient to establish human dosing, safety, or efficacy.

What Is Missing

No double-blind, placebo-controlled trial in humans has been published. No pharmacokinetic data in humans has been peer-reviewed. No established therapeutic dose, no defined half-life in human plasma, and no long-term safety profile in humans exist. The Endocrine Society's 2023 position statement on unapproved peptides notes that "the absence of human pharmacokinetic data for many investigational peptides makes extrapolation from animal studies inherently unreliable for clinical decision-making." [12]

The FDA's own Category 2 designation reflects this gap. The agency has not concluded that BPC-157 is harmful. The agency has concluded that present evidence does not support legal compounding for human use.

What Michigan Patients Should Do Instead

Patients seeking BPC-157 for specific conditions should have a direct conversation with a licensed physician about what evidence-based alternatives exist for their situation.

Alternatives for Gut Health

Patients seeking gut-healing effects attributed to BPC-157 may benefit from evaluation for SIBO, intestinal permeability, or inflammatory bowel conditions using standard diagnostic workup. Treatments with established evidence include aminosalicylates for mild-to-moderate ulcerative colitis, biologic therapies for Crohn's disease, and dietary interventions studied in controlled trials. [13]

Alternatives for Musculoskeletal Healing

Platelet-rich plasma (PRP) therapy for tendon injuries has a larger human evidence base than BPC-157, though results are mixed depending on the specific condition. A 2021 Cochrane review of PRP for lateral elbow tendinopathy (N=640 across 10 trials) found small short-term benefits over placebo for pain outcomes. [14] PRP is legally available from licensed providers in Michigan.

Working With a Telehealth Provider

HealthRX physicians can evaluate a Michigan patient's specific clinical situation, review what alternatives carry genuine evidence, and flag when a patient may qualify for participation in an IRB-approved research study. Patients interested in novel regenerative therapies are not without options. Those options just need to sit within a legal and evidence-supported framework.

Frequently Asked Questions